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Letter from the Editor

Dear Reader,
I first started working with Osmosis as a Sophomore
when Alex Long was preparing to gather together its
second issue. He heard through the grape vine that I
knew how to use Adobe InDesign. At first, I saw Osmosis
as purely a healthcare magazine, and as a non-pre-med,
just-pre-graduate-school student— I thought it wasn’t
for me. Through my ~3 years with Osmosis, I have come
to the conclusion that Osmosis is NOT just a healthcare
magazine, and contrary to our title, it is NOT just a science
magazine. Osmosis is for everyone. Osmosis is for the prelaw, the environmentalist, the faculty, and the conscious
citizen. I am so grateful that I have been able to watch
Osmosis grow through my time at UR, and I’m even more
grateful that some loyal Osmosis writers have been here
since the beginning. Adriana Grimes is a graduating senior
that has been writing since the first issue! I hope that in the
future we are able to gather even more loyal team members
and continue to grow in the right direction. I know from personal experience that Osmosis has helped me grow
in the right direction. Throughout my short scientific career, Osmosis has reminded me of the importance of
communicating science to a wider audience. As I prepare to graduate and go off to graduate school, I know I
would not have had nearly the same undergraduate experience if it was not for Osmosis. Good luck to next year’s
editor, Anthony Isenhour, I know I’m leaving Osmosis in good hands :)
Your editor,
Mickey Murvin
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Can a piece of gum
keep you running?
Najnin Rimi
than 50 percent of adults over the age of 18
M ore
drink coffee every day.1 Students on our own campus are not unfamiliar with the idea of a cup of coffee,
or more, a day. But, could there be an alternative to this
morning routine? Do we have to run on Dunkin? Kent
Chen and Ryan Yoshimura worked with surgeons from
UCLA to develop an exciting new energizer that would
provide better results than the energizers used in the
past. In 2015, they introduced Neurogum to the market.2 Its purpose is to boost energy, cognition, and focus
whether it is to study for a test or run a mile.
Neurogum contains natural caffeine, L-theanine, and B-vitamins that were combined to give a
longer attention boost than regular caffeine. Forty
milligrams of caffeine was incorporated into the gum to
reduce the risk of Alzheimer’s disease, as well as dementia. Several studies examining the relationship between
caffeine and dementia have agreed that caffeine does
play a role in protecting against the onset of Alzheimer’s
disease and dementia-related diseases. A linear study reviewing other studies, illustrated that the results, overall,
presented agreements under various conditions.3
L-theanine is an amino acid contained in teas,
such as green and black tea, and is said to be a complement to caffeine. It is suggested that L-theanine can
enhance the user’s focus, while also decreasing the negative effects of coffee, such as restlessness and stomach
discomfort, and stress.4 Sixty milligrams of L-theanine
is added, which is a greater than the amount of caffeine
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in Neurogum. The L-theanine directly affects brain waves,
called alpha waves, which reduces stress without the somnolent effects of relaxation.5 Usually, this ideal reaction
from L-theanine is not found within a normal cup of tea,
which contains only about 20 milligrams of the substance.
The 60 milligrams of L-theanine added is equivalent to
three cups of tea in one dense, small piece of gum.
The last of the ingredients include vitamins B6
and B12. Vitamin B6 assists with the production of neurotransmitters6; while, B12 helps produce DNA.7 These
vitamins have many other functions as well, but they are
also added in combination with the caffeine and L-theanine to promote the effects of all ingredients. This combination of ingredients allows the gum to extend cognitive
function within the body of its consumer.
Theoretically, almost every aspect of this gum and
its production plays a role in creating the desired effects
for consumers. For example, this gum is made using a
cold compress rather than applied heat, which allows it to
maintain all of its ingredients upon utilization.8 The creators also emphasize that the route of administration for
this product maximizes its ingredients, as well. Absorption via the oral mucosa is heavily understood to be faster
and more efficient than digestion, which supports the idea
of a gum rather than a drink.8 The thoroughness of their
research further extends the value of this product. They
prove its value appreciably in their written work, as they
justify other decisions when manufacturing this gum that
help maximize the ingredients. This product is a seemingly easy-to-use replacement for coffee, and with zero grams
of sugar, Neurogum may be worthwhile for busy students
seeking healthier lifestyles.
References
1. Chan, T. H. (2014, February 28). Coffee by the Numbers. Retrieved from https://www.
hsph.harvard.edu/news/multimedia-article/facts/
2. STRV. (2018). Wrap-up: Tech Talk with NeuroGum's Ryan Chen and Kent Yoshimura.
Retrieved from https://www.strv.com/blog/wrap-up-tech-talk-with-neurogums-ryan-chenand-kent-yoshimura
3. Eskelinen, M. H., & Kivipelto, M. (2010). Caffeine as a Protective Factor in Dementia and
Alzheimers Disease. Journal of Alzheimers Disease, 20(S1). doi:10.3233/jad-2010-1404
4. NEUROGUM™ INGREDIENTS AND USE. (2018). Retrieved from https://neurogum.
com/pages/neurogum-ingredients-and-use
5. Nobre, A. C., Rao, A., & Owen, G. N. (2008). L-theanine, a natural constituent in tea, and
its effect on mental state. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/18296328
6. Office of Dietary Supplements - Vitamin B6. (2018). Retrieved from https://ods.od.nih.
gov/factsheets/vitaminb6-healthprofessional/
7. Skerrett, P. J. (2019, February 11). Vitamin B12 deficiency can be sneaky, harmful. Retrieved from https://www.health.harvard.edu/blog/vitamin-b12-deficiency-can-be-sneaky-harmful-201301105780
8. Yoshimura, K., & Chen, R. (2016). U.S. Patent No. WO2017105564A1. Washington, DC:
U.S. Patent and Trademark Office.
YNovember 13, 2018, from https://www.shape.com/health-eating/diet-tips/what-is-biohacking-nutrition-science
[xi] Detwiler, J. (2018, June 25). I Hacked My Body So You Don’t Have To. Popular Mechanics. Retrieved November 13, 2018, from https://www.popularmechanics.com/science/
health/a21272160/biohacking
[xii] Webb, S. (2017, October). Bootstrapping Biology. BioTechniques, 63(4), 152-156.
https://www.future-science.com/doi/pdf/10.2144/000114594
[xiii] Blazeski, G. (2014, May 1). The Need for Government Oversight Over Do-It-Yourself Biohacking, the Wild West of Synthetic Biology. Seton Hall University eRepository.
Retrieved November 13, 2018 from https://scholarship.shu.edu/cgi/viewcontent.cgi?referer=https://scholar.google.dk/&httpsredir=1&article=1411&context=student_scholarship
[xiv] Wolinsky, H. (2016). The FBI and biohackers: an unusual relationship. EMBO Reports, 17(6), 793-796. https://doi.org/10.15252.embr.201642483
[xv] Shinde, S. & Meller-Herbert, O. (2017, June 12). Biohacking. Anaesthesia, 72(7),
909. Retrieved November 13, 2018 from https://onlinelibrary.wiley.com/doi/full/10.1111/
anae.13952

Bingeing on Carbs might make you drunk?
Anthony Isenhour
loves eating too many carbs and realistically
E veryone
the occasional food-binge doesn’t harm the body

very much. For some people, however, it can. For people in the United States who have been diagnosed with
Auto-brewery Syndrome, or Gut Fermentation Syndrome,
carbo-loading (eating copious amounts of carb-heavy
food at once) can have some legal and behavioral consequences.
Auto-brewery Syndrome is a condition where the
yeast within your gut produce ethanol through fermentation instead of traditional aerobic respiration. For people
with this condition who eat large amounts of carbs in
one meal, they end up with low levels of alcohol intoxication.1 Scientists have known about this
phenomenon for about a century, describing it as “abnormal gut syndrome,”
“germ carbohydrate fermentation,” and
“intestinal carbohydrate dyspepsia” as
far back as 1912.2
This syndrome has been shown
to affect adults and children and could
be a possible cause for sudden infant
death. People with this condition can
also experience side effects such as
hangovers, belching, disorientation,
and chronic fatigue.1 Having a gut that
can make its own alcohol seems fun,
but controlling it isn’t as easy as you
might think.
Auto-brewery Syndrome
happens because the yeast within the
gut go through anaerobic respiration,
also known as fermentation. This
means that when breaking down the
sugars from the carbs you eat, they produce ethanol as a
byproduct. Your liver typically metabolizes and breaks
down alcohol, but this extra production by yeast leads to
an increased alcohol content in your body even leading
to getting drunk. In treating this unintentional alcohol
intake, doctors typically recommend low carbohydrate
diets, as well as probiotic supplements to increase the
amount of normal bacteria in your gut.1
Because individuals with this syndrome do not
always know when it happens, multiple people have attempted to use this syndrome as a drunk-driving defense
in court. In 2015, a woman from upstate New York was
charged with a DWI (driving while intoxicated) hours
after having had her last drink. When pulled over while
driving with a flat tire, her blood alcohol content (BAC)
was 4 times over the legal limit. She was taken to the
hospital, as standard protocol for this BAC level, but was

released because she presented no symptoms. In further testing she was found to have an increased alcohol
tolerance that correlates to the level of functioning
alcoholics. Her charges were dismissed by a judge after
presentation of her possessing this syndrome.3
In early March of 2019, however, a man from
Maine attempted to use this syndrome as a defense for
his own DWI. His appeal was denied, but not strictly in
response to whether or not he had this syndrome. The
judge felt that the possibility of using an “ignorance”
approach as a legal loophole to drunk driving made the
ruling a particularly important one. The judge made
clear his dismissal of the appeal was not on the grounds
of the man having this syndrome or not, but
that his witnesses attesting to this appeal
were untrained or not provided in a
timely manner.4 This syndrome does
raise the question: Can individuals
with Auto-brewery Syndrome
be convicted for driving while
intoxicated if they have BACs
that are unintentionally over the
legal limit?
While being able to get drunk
after eating too many carbs may
seem fun, individuals with this
syndrome struggle with the
fluctuating levels of intoxication they experience. Additionally, they may face unintentional
conflicts with the law, as well as the
detrimental effects of continuous alcohol
within their bodies.
References
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Journal of Nutritional Biochemistry. 14. 115-120. 10.1080/13590840410001734965.
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1 Dec 2015. https://www.cnn.com/2015/12/31/health/auto-brewerysyndrome-dui-womans-body-brews-own-alcohol/index.html
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The science of Fetishes
Adriana grimes

A

fetish is defined by the Oxford Dictionary as
“a form of sexual desire in which gratification
is linked to an abnormal degree to a particular object,
item of clothing, part of the body, etc.”1 The diagnostic
statistical manual (DSM), which defines psychological
disorders,2 has also defined fetishes. Fetishes, however,
are not defined as a disorder unless they confer a serious
or significant detriment or distress for the person.3 Most
individuals who self-describe as having fetishes or being
fetishists do not fall into the category of having
clinical impairments due to the fetish.2
So how do sexual fantasies differ
from fetishes? Sexual fantasies are
broader than fetishes and include
sexual desire for certain behaviors
but may also include fetishes. This
article aims to examine fetishes as
defined by the Oxford Dictionary
in which the person is not clinically impaired. In other words, this
article will explore fetishes between
consenting adults for the sexual enjoyment of all parties
involved.
So how common are fetishes and “deviant” sexual fantasies? Unsurprisingly, this is an under studied
field. Thus, the data has come from a variety of places.
The two main sources are the internet and clinical case
studies (when someone sees a therapist). Canadian
researchers conducted a study of around 1,500 adults to
see which sexual fantasies are common and which are
rarer.4 Of the 55 sexual fantasies studied, only two fantasies were found to be rare, and nine were found to be
unusual for men and women.4 Thirty fantasies were described as common for one or both genders; while, only
five were found to be typical.4 The researchers caution
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against taking these results too seriously, as the sex surveys are likely to attract people who are more comfortable
in their sexuality and sexual behaviors than those who are
not.4 One interesting find between men and women was
that women are more likely to have a submissive fantasy
(30-60 percent of those surveyed), and men are more
likely to have a dominant fantasy (40-60 percent).4 As in,
women are more likely to want to be spanked, tied up,
whipped, and overall dominated; whereas, men are more
likely to want to perform dominating behaviors. However,
a significant portion of men also have sexual submission
fantasies and women also have sexual dominant fantasies.4 It is clear that many of what individuals outwardly
consider to be deviant sexual fantasies are not, in fact, as
abnormal as they appear. A cursory internet search performed by anyone with Wi-Fi will only drive that point
home.
		
Of fetishes, which are the most common?
A survey of nearly 400 discussion groups, which looked
at approximately 5,000 individuals, calculated the prevalence of different fetishes.5 They found that fetishes for
body parts and objects related to the body were the most
common at 33 and 30 percent, respectively.5 Preferences
for other people’s behavior comprised 18 percent; while,
a person’s own behavior and social behavior each made
up 7 percent.5 Objects unrelated to the body made up
just 5 percent.5 Within the category of
body parts, the most frequent by a large
margin is feet podophilia, at 47 percent
relative frequency.5 This is followed by
body fluids (urine, feces, blood, etc.) at 9
percent and body size (tall, short, weight,
etc.) also at 9 percent.5 With regards to
objects associated with the body, the most
common are objects worn on the legs and buttocks at 33 percent, followed closely by footwear at
32 percent.5 The next largest category is underwear at
12 percent.5
Why and how do humans develop fetishes? There
are two main theories to explain why and how humans
develop fetishes. One of the most popular is the “signals
crossing” theory, which helps explain the etiology of foot
fetishes.6 In the human brain, the senses are mapped; specific locations in your brain correlate to specific locations
on the body.6 The part of the brain that is triggered when
the genitals are stimulated is adjacent to the part of the
brain that is mapped to the feet.6 It is theorized that some
people have an overlap in neurons of these areas.6 Basically, the boundaries of the map overlap, meaning that
feet can cause sexual arousal in a person.6 This includes
looking at, touching, and smelling feet, either their own
or another individual’s. This is what is defined as a foot
fetish. This also may be the reason that foot fetishes are

one of the most popular fetishes.5
The second theory is “early childhood imprinting”, which
states that early childhood experiences are reflected in
the fetishes present in adulthood. Within this, there are
two proposed theories: the conditioning and the trauma
theory. The conditioning model theorizes that fetishes
develop when a stimulus is paired with sexual thoughts
or behavior.3 Studies have shown that men can be conditioned to have erections from traditionally non-sexual
stimuli (i.e. types of clothing) if they were first paired
with sexually explicit photographs.7 Researchers paired
sexually explicit photos with a pair of women’s boots and
colored geometric figures and found that some men could
develop erections in response to the non-sexual stimuli alone. These results, however, should be taken with a
grain of salt due to small sample sizes and lack of control
conditions.7 The trauma model is based on the idea that
fetishes are rooted in either emotionally or physically
traumatic experiences in childhood or adolescence.3 This
also includes unresolved emotions from childhood or
growing up in sexually restrictive households.3 However, most experts agree that the conditioning and trauma
models do not fully account for the development of
fetishes because not everyone develops fetishes and some
stimuli are fetishized more easily.
There are a lot of reasons why sexual fetishes
could develop and in whom they develop. There are interesting patterns that are present in preliminary studies,
but more in-depth research is needed before any concrete
statements can be made about fetishes and sexual fantasies.
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ancer is a deadly disease affecting and
killing many people every year. For 2019,
the estimated number of new cancer cases
exceeds 1.5 million, and the estimated number
of deaths caused by cancer exceeds six-hundred
thousand.1 Treatments for cancer certainly exist;
although current treatments are often costly and are
not always effective in the long-run. The treatments
also come with side effects often associated with
the destruction of healthy, noncancerous cells.
The expansion of alternatives for treating cancer
is a constant objective for the medical community,
and researchers are experimenting with many new
solutions in order to provide new opportunities to treat
cancer. One potential treatment in development is
snake venom, a substance that is normally poisonous
to humans in its unmodified form.
Although snake venom as a whole can be
harmful to humans, it is composed of many different
proteins, enzymes, and carbohydrates. If the different
molecules constituting the venom are extracted and
isolated, the individual molecules can provide benefits
for humans without the harmful effects of the entire
venom. For example, the drug captopril is derived
from snake venom and treats high blood pressure and
heart failure. As long as the entire venom is not used,
the separate components can elicit healthy effects in
humans. In the 1940s, researchers began isolating
enzymes and non-enzyme proteins from snake venom
and experimented with the proteins for effects on
tumor cells. Clinical testing with the venom became
more prevalent from the 1960s onward.2, 3
The proteins in snake venom harbor a variety
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of cancerfighting characteristics.
One such type of protein is the disintegrin.
Disintegrins are non-enzymatic proteins found
in snake venom and inhibit angiogenesis, the
development of new blood vessels. Angiogenesis
allows tumor cells to invade nearby healthy tissue and
metastasize. Treatment with disintegrins has been
shown to suppress the spread of tumors due to the
antiangiogensis activity of disintegrins.3
L-amino acid oxidases (LAAOs) are enzymatic
proteins found in snake venom and demonstrate
anti-tumor effects. LAAO converts L-amino acid to
alpha-keto acid and releases the byproducts ammonia
and hydrogen peroxide. Hydrogen peroxide is a major
proposed mechanism of LAAO-induced toxicity, as it
can act as reactive oxygen species (ROS) that can
diffuse into cancer cells and cause cell death. Studies
have shown that the effects of ROS are more likely to
harm cancer cells than normal cells, possibly due to
the higher metabolic activity present in cancer cells.
The higher metabolic activity leads to higher levels
of ROS in cancer cells; hence, the cancer cells are
more susceptible to further increases in ROS levels
than normal cells. The evidence of selectivity of LAAO
activity towards cancer cells is beneficial for cancer
therapy, as the enzyme does not seem to have a high
potential to harm healthy cells.4
Metalloproteases (MPs) are another group of enzymes
derived from the venom and can also exhibit antitumor activity.5 One type of MP, known as jarahagin
(produced by the species Bothrops jararaca), has
demonstrated cytotoxic effects on melanoma cells,
as well as inhibition of cancer cell adhesion.6 Cell
adhesion contributes to tumor spread; thus, by
inhibiting adhesion, jarahagin can prevent metastasis,
which is the spread of cancer to a secondary site.
Phospholipase A2 (PLA2) is another enzyme

belonging
to snake
venom and has
demonstrated cytotoxic and
antiangiogenesis effects.5
Lectins (proteins that bind to sugars) belonging
to snake venom have been shown to inhibit the
growth of certain types of cancer cells, such as renal
and pancreatic cancer cells.5 The proteins have
also demonstrated cytotoxic activity. In a particular
experiment, the lectin B1L, belonging to Bothrops
leucurus venom, was tested and induced apoptosis on
a variety of cancer cells, including myeloid leukemia
cells, lung carcinoma, and larynx carcinoma cells.
Furthermore, healthy cells were not harmed by the
protein.7 Thus, snake venom lectins can be especially
helpful in treating certain types of cancer.
The process of collecting the venom and
determining its effects on cancer takes multiple
steps. The species of snake from which the venom
is collected depends on the proteins of interest, as
the type of venom varies among species. It may be
easier to collect venom in the summer as opposed
to the winter, as the venom is more liquefied in the
summer.8 Once the species is identified and captured,
the snake must be kept in conditions suitable for living.
A snake can die when kept in conditions unlike its
natural habitat, and high occurrences of snake deaths
could shift a vulnerable species closer to becoming
endangered.2 Once the venom is collected, the
proteins must be isolated using various purification
techniques, such as size-exclusion, ion exchange, and
affinity chromatography. Edman sequencing can be
used to determine the sequences of small proteins, if
necessary.9 Once the individual proteins of the venom
are identified and isolated, researchers can test the
effects of the proteins on cancer cell activity.
The isolation and utilization of snake venom
components is a valuable cancer-fighting technique
but is not without its flaws. The immune system can
possibly react to foreign proteins injected into the
bloodstream. Immunosuppression may help prevent
rejection of the proteins by the immune system, but
would also render the body vulnerable to infectious
agents. Encapsulation of the proteins in nanocarriers
for slow, controlled release of the proteins may help
prevent adverse reactions by the immune system.

The technique of encapsulation, however, has not
fully been mastered and is currently in development.3,
10
Furthermore, the mechanisms of action of many
cancer-fighting proteins have not yet been confirmed,
which is why many of these proteins are not yet
available for purchase from pharmacies.11 Until the
exact behavior of the snake venom components
are made certain, there is no guarantee that these
proteins cannot destroy healthy, noncancerous cells.
Although many of the proteins have demonstrated
selectivity towards tumor cells in experiments, further
research should be done to confirm the abilities of
these molecules to discriminate between cancerous
and healthy cells and to determine potential methods
to circumvent any possibility of the proteins harming
healthy cells.
Snake venom as a treatment for cancer is
promising and could be an effective alternative to
current treatments. Whether or not the use of snake
venoms would be more cost effective or less painful
than current treatments has not yet been confirmed,
as the treatment is not a common practice. Further
research on the behavior of these proteins and on
potential costs of treating cancer patients with the
venom should provide more insight about the value of
the treatment. In the future, when more information is
made available, snake venom could potentially serve
as an incredibly valuable alternative to current cancer
treatments.
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Why Do We Need the Flu Shot Every Year?
There is a need for a new vaccine every year due to

Necessity of Receiving the
Flu Vaccine and
Recent Research Trials
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Lizzie Godschall
To this day, smallpox is the only disease confirmed to be
eradicated worldwide. This would not have been possible without the first widely utilized vaccine developed
nearly 200 years prior by Edward Jenner. Inspired by
Jenner’s methodology of using the cowpox virus to protect against smallpox in humans, vaccine innovations
and their significance to public health took off after Louis Pasteur’s discovery of the rabies vaccine in 1885.
Vaccines are perhaps the greatest immunological feat
to this day. So why are people still so averse to getting
vaccinated, especially for the flu? Encouraging people
to get their annual flu shot and persuading the public of
its effectiveness are two vital measures for preventing
flu-related hospitalizations and deaths.

significantly reduces flu-related hospitalizations and fatalities (Nichols, 2018). The effectiveness of the flu vaccine varies from year to year depending on how well the
projected vaccine antigen sequences matches the actual seasonal viral antigen. Although some years have
better predictions than others, the overall effectiveness
of the vaccine tends to be 40-60% (CDC).

Flu History
World War I played a significant role in the first influenza outbreak. The war brought the mass mobilization
of over 60 million soldiers with significantly different
backgrounds and immune systems to highly concentrated war zones in Europe. This, coupled with years
of unsanitary lifestyles, facilitated high transmission
rates leading to the H1N1 influenza pandemic outbreak
in 1918 (Matthews, 2014). Over 50 million people died
and many more were infected by the end of this pandemic. At the time, the only preventative measure that
was exercised was quarantine.
About twenty years later, the influenza A and B viruses
were isolated in the lab. Although vaccinations against
this virus have been in development since the 1930’s,
numerous clinical trials have debunked the effectiveness of the influenza vaccine for decades after the
1918 pandemic (National Vaccine Information Center).
A century after the first influenza outbreak, the CDC reported that the flu vaccine decreases the prevalence of
flu related illness, hospitalization, and death, especially
in young children and elderly people. Numerous studies have suggested that the trivalent influenza vaccine

12

s1
mosis SPRING 2019
magaz ine

Waves of first influenza outbreak 1918 (Potter, 2008)

What is the Flu Virus?
The influenza virus is characterized by two envelope
proteins. Hemagglutinin (HA) is the protein that allows
the virus to attach to host cells, while neuraminidases
(NA) release the virus from the host cell (Morgridge).
There are sixteen known types of hemagglutinin and
nine known types of neuraminidase, which gives 144
different possible combinations of these proteins (Morgridge). Different viral strains contain distinct hemagglutinin and neuraminidase proteins, such as H1N1,
the most common influenza A known as the “swine flu.”
Influenza vaccines contain three to four of the most
common influenza strains, which are typically H1N1,
H2N2, H2N3, and influenza B. The flu vaccine tends to
be twice as effective in preventing H1N1 than H2N3 and
influenza B (Rondy et al., 2018). This is one reason why
the vaccine is not effective for everyone.

antigenic drift. The antibodies that your body produced
in response to last year’s flu shot are specific to the viral
antigens from that year’s version of the vaccine. When
a mutated version of that virus enters the body, these
antibodies are no longer able to evoke an immune response (Potter, 2008). Since the virus mutates slightly
each season, new vaccines with slightly different antigen combinations must be developed to recognize
the hemagglutinin and neuraminidase proteins of the
mutated virus. Once the vaccine is administered, your
innate immune system will create a cascade effect to
activate B-cells to produce antibodies. If you were to
contract the influenza virus, ideally your body would already have the necessary antibodies to fight the virus
and produce minimal flu-like symptoms. The vaccine
enables our bodies to combat the virus by generating
antibodies in advance. Within two weeks of vaccination,
the adaptive immune system should have generated
appropriate defenses against contracting the seasonal
strain of the flu (CDC).
How Do I Choose a Vaccine?
The two most conventional types of flu vaccinations are
egg based. These include the killed vaccine, taken as
an intramuscular shot or live attenuated nasal spray
vaccine (CDC). The killed vaccine involves injecting
a fertilized hen egg with the influenza virus and later
harvesting and purifying the viral fluid to acquire the inactivated viral antigen. The live attenuated vaccination
is a weakened version of four common strains of live
influenza viruses. This attenuated nasal spray is not
recommended for people over 50 or immunodeficient
recipients. Live attenuated vaccine is cold adapted, so
the virus cannot survive and replicate in the warm environment of the lungs and cause an infection. Although
vaccines are developed using viruses, the flu shot cannot cause the flu.
Innovations within the past five years include cell-based
and recombinant technology (Nation Vaccine Information Center). The inactivated cell-based flu shot is produced in a similar way to the egg-based killed vaccine,
but the viral antigen is extracted from a mammalian cell
culture rather than utilizing chicken eggs. The recombinant vaccine requires isolating a gene expressing viral
specific protein. Typically the gene encoding for HA is
injected into an insect virus, so it can be replicated within insect cells. This process is faster than other methods because the virus does not need to undergo an attenuation phase to grow in eggs or cell cultures (CDC).
Recent Trials for Vaccine Development

agglutinin and has the most promising immunological
success rate according to data acquired so far from the
clinical trials (Taylor, 2018). About a dozen more influenza universal vaccines, each founded upon slightly
modified approaches, are in the earlier stages of clinical trials. Increased public cooperation coupled with
advancements in biomedical vaccination technology
will hopefully lead to the stark decrease and eventual
eradication of influenza viruses.
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Since the first influenza outbreak 100 years ago, a universal flu vaccine may become available in the near future. BiondVax’s M-001 peptide vaccine has reached a
phase 3 clinical trial in Europe. Instead of targeting the
seasonally variable antigen surface of hemagglutinin
and neuraminidase proteins, M-001 targets nine highly conserved epitopes of the flu virus. These epitopes,
which are part of an antigen that are recognized by the
immune system, don’t change seasonally. So, ideally,
you would only need one universal flu shot that would
be effective for your lifetime. This approach allows for
protection against all strains of influenza virus. Getting
the universal vaccine in conjunction with the seasonal
vaccine stimulates antibody production against hemPage Design by Molly McCoy

Lack of Diversity in Genomics Research
Savannah Del Cid
Precision medicine is a movement that seeks to serve a patient’s individual medical needs with a tailored level of treatment. Such a practice requires an essential framework of
genetic information to allow doctors to make accurate treatment decisions. Genome-wide association studies (GWAS)
provide massive amounts of information for databases, such
as the GWAS Catalog; however, there is an apparent lack of
diversity in the genomics data available to researchers and
drug-developers. The majority of participants in GWAS are
of European descent. As of January 2019, 78 percent of genetics contributed by GWAS have been of European descent;
while, only 22 percent are minorities (Yeager 2019). Stemming from a history of discrimination and unfair logistics,
the lack of diversity in genomic databases undercuts the accessibility and function of Precision Medicine, and this issue
needs to be resolved.
After the completion of the human genome project in 2003,
the ability to conduct GWAS and create a database of genetic
information became possible and affordable. Over the past
two decades, the data on human genetics has grown. Based
on this growth, one would assume our knowledge of treatments based on the unique genetic makeup patients would
be vast and precise by now. At times, however, the proclamations of Precision Medicine overlook the history of genetics— the percentage of European genetics in the GWAS
Catalog remains the majority, even if they are not the majority by global population (Popejoy 2016). To understand
how the lack of diversity in genetic databases developed,
one must look at the questionable ethical history, medical
assumptions, and objective logistics of genetic studies.
Genetic research has had its share of ethically turbulent moments. As discussed by journalist Chou, the conversation between the scientific community and the public often struggles
to distinguish between race and ethnicity of participants in
genome studies (Chou 2017). The social construction of race
is false, based on external phenotypes like skin color, and not
backed by science because significant genetic variation exists even within the historical “five races”—African, Asian,
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European, Native American, and Oceanian— that have been
used as a standard of categorization (Chou 2017). The genetic
isolation of populations within the human species results in
countless variations in phenotype and contributes to general
ethnic differences and tendencies, which can greatly impact a
patient’s health and lifestyle from a medical perspective. Thus,
using ethnicity to minimize variables when categorizing data
experimentally can be useful, but the variation within ethnicity remains and makes constructing GWAS difficult (Chou
2017).
Another ethical factor, besides the issue of distinguishing
race from ethnicity when gathering patient samples, is the
blatant harm genetics research has inflicted on uninformed
populations. One of the most striking examples concerns the
Havasupai tribe in Arizona (Santos 2008). The Havasupai
tribe agreed to a genetic study proposed by Arizona State
University in the 1990s and were under the impression that
the researchers would report the results and provide insight
into the high frequency of type-2 diabetes in the tribe (Santos
2008). However, the Havasupai never received a report from
the study; in fact, the cell lines produced from the tribe’s samples were distributed among other universities, where studies
deviating from the original agreement were conducted without the Havasupai’s consent (Santos 2008). Consequently, the
Havasupai filed lawsuits on the grounds of “exploitation and
violation of civil rights” (Santos 2008). Numerous incidents
similar to this have historically occurred in minority populations; a well-known example being the exploitation of cells
from Henrietta Lacks, also known as HeLa cells. With such
an unethical history of interaction with research endeavors,
minorities commonly refuse to participate in genetic research
studies, which contributes to the lack of diversity in GWAS
(Santos 2008).
Along with ethical issues, genetics research has also been
conducted with certain assumptions in mind that simply do
not hold true. As Adebowale Adeyemo, deputy director of the
Center for Research on Genomics and Global Health at the
National Human Genome Research Institute, highlights in an

interview, there have been assumptions that destitute populations and minority populations do not need genomic testing
because infectious illnesses are a more prevalent and pressing
concern than genetic diseases in such populations. However,
over the years it has been proven that genetic diseases, such as
heart disease and other chronic diseases, are also a significant
concern in poor populations and minority populations just as
in affluent or majority populations (Mullin 2016).
Moreover, the genomes of many minorities and indigenous
populations are more difficult to decode because of the numerous diverse communities within each minority and indigenous population. This complexity appears to deter researchers because of the assumptions that the complexity will not
provide accurate data to produce treatments (Santos 2008).
For those few who do take on the challenge, the difficulty
comes with great reward in discovering mutations and variants that often prove useful for medicine (Santos 2008). The
unique qualities of minority and indigenous genomes provide
greater knowledge on how genetics influence drug interactions during treatment and other health issues like diabetes
(Popejoy 2016). Therefore, concerning medical care, minority
patients require just as much genetic data as the European
patients, if not more because of the great diversity within the
genomes of minority and indigenous populations that can
provide great benefit to treatment and drug development.
While ethics and assumptions show how the research community has been wrong in its execution of genetic studies,
some aspects of the logistics of GWAS can hinder the ability to achieve diversity in studies. The primary logistical issue
connects to historical points already mentioned. If people
do not wish to contribute their genetic information due to
historical oppression, discrimination, and unethical practice

under false assumptions, then it proves extremely difficult to
gather data on such populations today. The inability to attain
samples from minorities slows progress towards diversifying
the GWAS Catalog and other genetic databases, despite efforts by programs like All Of Us, which was created by the
NIH in 2018 to develop a database of at least a million diverse
patient genomes (Yeager 2019).
Due to how long the databases have been filled with European majority, another logistical issue stems from the analytical models used to process the data produced by these massive GWAS. Analytical methods called ancestry metrics are
used to process genomic data found in GWAS databases, but
these metrics do not properly analyze an individual of a diverse background (Bustamante 2011). As a result, our current
methodology of analysis likely produces a significant amount
of error for genomes that carry more variants and deviate
from the more homogenous populations that the metrics are
based upon (Bustamante 2011).
The history of genetics research is riddled with ethical
and logistical issues that have contributed to the present lack
of diversity in GWAS. Incidents such as sampling bias based
on supposed “race” and violation of minority patients’ consent rights have caused logical issues for present day GWAS
that seek to gather diverse genomes but cannot due to a lack
of trust in research. Thankfully, several programs, similar to
All Of Us, have been commissioned in recent years to create a
better relationship between the public and researchers. While
the past cannot be changed, the way in which future GWAS
are constructed and conducted can be adjusted to achieve a
genetic database that properly represents and provides Precision Medicine for the entire human species.
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4, 1974, a nine-year-old boy was raped
O ninMarch
his home in Lake Wales, Florida. When the

police arrived, the boy described his assailant as possibly
17 or 18 years old with a mustache and thick sideburns
and named “Jim” or “Jimmy.” After being identified in a
photograph lineup by the victim, Jimmy Bain, who said
that he was at home watching television with his sister,
was arrested and charged with child sex abuse, kidnapping, and burglary/unlawful entry. During the trial, the
prosecutors relied on both the photograph lineup and
semen that had been found at the scene. The analyst
identified that the semen came from a person with Type B
blood, but Bain had Type AB blood. However, because the
analyst said that Bain’s blood type was a weak A, he could
not be excluded from the list of suspects. He was eventually convicted and sentenced to life in prison based on
shoddy forensic science. Bain was serving his life sentence
when Florida passed a statute in 2001 that allowed for
cases to be reopened for DNA testing.1 After five failed
petitions to the courts to reopen his case, he eventually
got the help of the Innocence Project, an organization that
seeks to exonerate wrongly convicted inmates using new
DNA testing. According to the Innocence Project, “364
people in the United States have been exonerated testing,
including 20 who served time on death row.”2 The DNA
evidence eventually exonerated Bain, who was released in
2009— 35 years after his conviction— and was awarded
$1.7 million by Florida. Bain’s story is one of many wrongful convictions that have been overturned by new DNA
sequencing technology.
In criminal cases where the perpetrator is unknown, detectives look for articles that may contain the
perpetrator’s DNA including hair, saliva, semen, sweat,
blood, or even skin cells. The cells are lysed, the DNA is
isolated, then amplified and multiplied using polymerase
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chain reaction (PCR). The DNA sequence can then be
used in short tandem repeat (STR) analysis. An individual
has 3-7 base pair repeats, called loci, distributed throughout their DNA. The type and number of loci repeats are
unique in each person. In STR analysis, these loci are
amplified and sequenced.3 Variability in a person’s STRs is
enough to differentiate between individuals, which allows
for DNA sequences to be compared between suspects
for criminal investigations. In 1994, the FBI established
the Combined DNA Index System (CODIS), a national
DNA database that allows for DNA comparison to known
criminals. However, this is not the only DNA database
that law enforcement uses. Third-party DNA sequencing
companies that analyze customers’ DNA sequences to
determine ethnicity or family lineage including 23andMe,
AncestryDNA, and LivingDNA have been known to share
data with police in investigations. According to 23andMe’s
website, they “do not share customer data with any public
databases” but “may be required by law to comply with a
valid court order, subpoena, or search warrant for genetic
or personal information.”4 These “voluntary” databases
have been used before in investigations. A 1993 murder
case was reopened in 2015 due to the new advances in
DNA testing and these private companies. Investigators
sent samples from the original crime scene to a private
DNA sequencing company and ran them through an
online genealogy website. The test connected the DNA to
Jerry Westrom. Using social media, the detectives followed Westrom, eventually recovering a napkin that he
threw out while eating a hot dog at his daughter’s hockey
game. The DNA on the napkin was found to match the
blood found at the crime scene, and in February, Westrom
was charged with second-degree murder.5 Although these
companies may be a powerful tool for investigators, their
practices call into question an individual’s right to privacy

with regards to their DNA, whether given voluntarily or
not.
DNA testing has also made its way to the Supreme Court. In Maryland v. King (2013), the Supreme
Court ruled that DNA swabbing can be considered part of
the regular arrest booking procedure alongside mug shots
and fingerprints. Thus, when a police officer swabs the inside of an arrestee’s mouth to collect DNA without cause,
the officer is not in violation of the Fourth Amendment,
which protects against “unreasonable searches and seizures” of “persons, houses, papers, and effects.” King was
arrested for attempted violence, burglary, and attempted
burglary. When he was booked, his DNA was run through
CODIS and matched DNA from an unsolved rape. King
was convicted of first-degree rape and sentenced to life
in prison. King appealed his case, arguing that the cheek
swab was an unconstitutional search in violation of his
Fourth Amendment rights against warrantless searches.
The Court ruled against King saying the search was not a
violation. Justice Kennedy, writing for the majority, said
that a cheek swab “involves but a light touch on the inside
of the cheek . . . The fact that an intrusion is negligible
is of central relevance to determining reasonableness,
although it is still a search as the law defines that term.”6
Essentially, because the swab is unobtrusive, it is not
unreasonable for a police officer to undergo a “search”
without cause. This allows for police officers to utilize the
wide capabilities of DNA testing to solve crimes without
needing to obtain a warrant. Although this would bring a
host of good in crime solving, it could be readily abused,
which the Fourth Amendment is meant to protect against.
Justice Scalia, writing a dissenting opinion in which
Justices Sotomayor, Ginsburg, and Kagan joined, categorically prevents officers from performing a search without
cause. The Court has always held that “no matter the
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degree of invasiveness, suspicionless searches are never
allowed if their principal end is ordinary crime-solving.”
Scalia continues saying that the Court’s ruling “will, to
be sure, have the beneficial effect of solving more crimes;
then again, so would the taking of DNA samples from
anyone who flies on an airplane, applies for a driver’s
license, or attends a public school.” The increasing capabilities of DNA testing should be carefully regulated just
as with any new technology that can have implications on
the legal system. As powerful as these new technologies
are for exoneration and crime solving, individuals’ privacy
should be given proper weight and protections in the face
of the extraordinary capabilities of DNA testing.
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t’s that time of the season again, as the sniffs and
coughs begin to rapidly spread throughout campus.
Despite how hard you try to avoid all who are infected,
no doubt you will wake up soon enough with a tickle in
your throat and a waterfall running from your nose. As a
college student, you can’t go all the way back home to your
family physician, and the university’s clinic is booked for
days. So, you drive to the nearest Walgreens and walk into
the MinuteClinic. Here, within an hour you’re able to check
in, get evaluated and diagnosed by a healthcare professional,
and walk out the door with a prescription in one hand and a
copy of your medical results in the other.

History

The MinuteClinic is one of the many branches of
retail clinics growing across the US as an alternative for
primary care treatment. First opened in 2001, retail clinics
began with a Rick Krieger’s frustrations when he was put on
a long standby, waiting for his son’s diagnosis and treatment.
Because of this frustration, Krieger became the cofounder
of the first MinuteClinic. It wasn’t until 2006 that these
retail clinics would rapidly expand with CVS Caremark
Corporation buying the rights to the MinuteClinic. This led
to the establishment of over 1,000 clinics within the next
five years. Now in 2019, there are over 2,800 retail clinics
throughout the US available for screening and diagnosing
patients (Burkle, 2011).

Why the rise in retail clinics?

Retail clinics have developed from the one value
that our culture holds highest: convenience. For retail clinics,
the convenience of widely-accepted insurance, low costs,
and flexibility in location and times acts as a catalyst to their
rapid expansion and takeover of the primary care market.
Before visiting any provider, insurance is the first concern
for any patient. The 2010 Affordable Care Act resulted in
an increased number of individuals able to gain insurance.
As a result, retail clinics thrive on their ability to accept
these, and many more different types of insurance, despite
what reimbursement they may receive. This includes private
insurances from employers to public ones such as Medicare
and Medicaid, which reimburse at lower rates than private.
Even after insurance, co-pays can still be an expensive chunk
out of any anyone’s pocket. The staff and model employed by
retail clinics, however, have shown to cost less than that of
other health providers. On average, a visit to any retail clinic
costs about $110 versus a range of $150 to $570 for a visit
to a physician, urgent care clinic, or the emergency room
(ER) (Mehotra et. al, 2009). These low costs, in comparison
to other medical providers, are a high incentive for patients
who aren’t able to afford the high costs of healthcare or
whose insurance doesn’t completely cover the costs of
physician visits.
Lastly, is the availability of these retail clinics— both
in location and hours. While the number of clinics in each
state varies, for 35 percent of Americans a retail clinic is
no less than a 10-minute drive away (Marsolf et. al, 2016).
The close proximity of these locations in combination with
extended weekday and weekend hours only widen the range
of patients able to be seen. In comparison, physician’s office
are usually a solo location that have limited hours on the
weekend, if any. This facets then severely limit the patients
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able to be seen in comparison to a retail clinic.

Are retail clinics helping or hurting?

Despite all the patients that retail clinics are
accessible to, due to their costs and availability, it’s important
to ask: Are patients getting the quality of care needed
by these retail clinic providers? According to studies, it
depends. A study done by Shrank and other researchers in
2014 looked at over 20,000 medical cases from 2009 to 2012
to study if a measured and objective standard quality of care
was met by these retail clinics. Their results showed that the
quality of care was not only competent, but in the case of
certain acute conditions, the quality of care was better than
other medical providers. In addressing common conditions
such as the flu or urinary tract infections (UTIs), retail
clinics can be excellent providers in terms of lower costs
and availability and an uncompromised quality of care for
patients.
Chronic conditions, on the other hand, are a
different story. Nitin Damle, MD and President of the
American College of Physicians (ACP), states, “We don’t
think there is enough evidence to say that they are able to
take care of chronic disease to manage complex problems.”
Chronic diagnoses can be intricate diagnoses that often
require a team of healthcare providers— each specialized
to address some aspect of your diagnosis, whether it’s a
nutritionist or a gastroenterologist. These types of teams
can typically only be established in a physician’s office or the
hospital.

Future of retail clinics

What will the role of retail clinics be in the future
then? While retain clinics continue to outcompete other
primary care providers in terms of convenience, patient
safety and quality of care comes first. This has been the basis
of rivalry between retail clinics and physicians as physicians
strongly believe there is no role for chronic care management
in retail clinics. While it may seem like the path ahead would
be filled with competition between these two in addressing
primary care shortages, another path is being paved.
Rather than attempting to outcompete each other,
physicians’ offices and hospitals have joined in collaboration
with retail clinics in order to bridge the gaps in patients. In
Ohio, Walgreens’ MinuteClinics are now partnering with
hospitals like the Cleveland Clinic. Through this partnership,
the two can evaluate all the facets of primary care to ensure
the delivery of what either system may lack in caring for its
patients. With that idea in mind, it’s important to note that
retail clinics can be an adequate, if not convenient, primary
care provider when used properly. However, these clinics
are not cure-alls, but rather a single facet in the healthcare
system of delivering care. By continuing to work together
and not against each other, the future looks bright for a more
integrated health care delivery system using a collaboration
between retail clinics, physician’s offices, and hospitals.
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12. What does a typical day look like for
you? If you can call it typical.

Interview With a Specialist:
Dr. Christopher S. Thomas, MD
Invasive Cardiology
Virginia Cardiovascular Specialists

1. When did you first learn of your interest in
medicine?
•

I always wanted to go into medicine. There was
no clear, inciting event that led me that way. In
general, I enjoyed figuring things out and putting
the pieces together to solve problems. I was
always drawn to the human element of working
with people and helping them through difficult
situations. These were the main reasons that I
pursued medicine.

2. How did you know it was right for you?
Did you know?
•

I knew I had the right skill set for medicine. I
liked directly helping people. I considered other
things, such as law, but none of them appealed
to me in the same fashion.

3. Where did you go to undergrad, and what
did you major in?
•

I attended UVA and majored in Biology and
American Politics.

4. Where did you go to medical school and
why?
•

I went to Eastern Virginia Medical School
(EVMS). I chose it because it was close to
home without being too close. I wanted to stay
in Virginia. I liked that it had a smaller class size
than VCU and I liked that I wouldn’t get farmed
out to other locations like UVA does.

5. What other passions do you have that are
either in medicine or outside of medicine?
•

I’m very interested in sports and music. I
was head assistant of the basketball team at
my old high school before my son was born.
Additionally, I am learning to play the piano right
now.
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A typical day involves a half day of clinic where I
see 10-12 patients, on average. The other half of
the day involves treating hospital patients. This
is when I do procedures or interpret studies, as
well as make phone calls to my patients.

16. What was your most challenging/difficult
case and why?
•

13. What was the path to your specialty?
(medicine-residency-fellowship?)
•
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anxiety to the job.

I graduated in 2002 from UVA. From there, I
worked for one year as an emergency room
scribe. I continued working from 2003-2005
while I earned a master’s degree in physiology
from VCU. I went to EVMS from 2005-2009.
Next, I did an internal medicine residency at
VCU from 2009-2012. I worked one year as
a hospitalist (inpatient medicine) at VCU from
2012-2013. Finally, I did my fellowship at VCU
from 2013-2016

6. What is your specialty?
•

17. Do you have a time that you experienced
failure or struggle in med school or
residency, and how did you overcome it?
•

Cardiology.

7. Where did you do your residency?
•

I did my residency and fellowship at VCU.

8. Years in Practice?
•

I am finishing up my third year.

9. What is your practice setting/employment
Type?
•

I work in a community setting for a private group.
I am currently on a partnership track.

10. What kinds of other practice settings
exist?
•

Many practice types exist; other cardiologists
are employed by a hospital corporation or by an
academic institution.

14. What is your favorite part about
Cardiovascular or about medicine in
general?
•

11. What does your specialty entail?
•

Cardiology involves both inpatient and outpatient
care. I perform cardiac catheterizations and
implant temporary internal pacemakers
and internal monitoring devices to measure
intracardiac pressure and arrhythmias.
Additionally, I interpret transesophageal
echocardiograms, Holter monitors, nuclear
stress tests, and PET stress tests. Other
types of cardiologists include interventional
cardiologists and electrophysiologists.
Interventional cardiologists put in stents, artificial
valves, occluder devices, and valve clips.
Electrophysiologists’ duties include pacemaker
and defibrillator implantation and ablations.
Ablations are procedures to make an electrical
map of the heart and then destroy abnormal
electrical tissue which leads to irregular heart
rhythms. This can be done by using cryoablation
(cold), radiofrequency ablation (heat), or lasers.

Cardiology is an extremely flexible and growing
field. Tasks, which were previously surgical in
nature, can now be done using catheters. It is
flexible in that you can be procedurally oriented
or never do procedures. I like to say that you
can customize your practice to whatever you
enjoy. You can wear scrubs all day and perform
procedures, or you can work in a clinical
setting and never see a drop of blood. The
field is also very cutting edge and guideline
driven with strong research predicating our
recommendations. It is very satisfying to directly
impact patients’ lives.

15. What is your least favorite part about
your job?
•

As a cardiologist, many other fields defer to
you as the final gatekeeper for a procedure
or decision. “If it’s OK with cardiology” or,
“cardiology has cleared them” are things that
are said and written all the time. If bad things
happen, it can be frustrating for people to look
at you when you really had nothing to do with
the outcome or situation. It is, however, neat to
be held in that regard, but it adds pressure and

In general, arterial procedures can be quite
difficult. You can follow the procedures and do
everything right, but you may still end up with
some bad outcomes. There are safe guards in
place to ensure that all of the instruments are
working properly, but, the “swiss cheese theory”
can still apply. There can be procedures where
“the holes” in all the bits of cheese line up. In
this analogy, it means that sometimes, things
can happen that are out of your control. The
hardest part is going into the next procedure with
another patient and maintaining your confidence.
Confidence is vital for working in a procedural
field.

Everyone fails and struggles at some point.
Long hours and lots of stress can be difficult to
manage. Often times, family and friends don’t
understand what you are going through. Many
decisions are made, and some are wrong. You
overcome it by being honest with yourself and
honest with your colleagues. Don’t be afraid to
ask for help; take advice from people who care.

18. What specialty(s) did you originally
think you were going to end up in when you
entered medical school? What changed?
•

I thought I would end up in either a subspecialty
of medicine or surgery. I wasn’t sure which one.
I wanted something with flexibility where I could
do many different things, as it keeps work from
getting mundane.

19. What was your favorite part about
medical school/residency?
•

The friends that I made through all of the steps
was the best part. It makes working hard more
tolerable and allows for you to lean on others
and become stronger.

20. What is one skill that you have that you
feel has helped you achieve all that you
have?
•

I think that I am pretty empathic. When you are
able to put yourself in another’s shoes and try
to better understand and appreciate another
person’s situation, it makes you and your
recommendations more effective because it
allows you to be both a better listener and more
persuasive.

21. What personality do you think are
required or necessary in Cardiovascular?
•

No specific personality is needed because there
are so many different types of cardiologists.

22. What is one piece of advice you would
give to those pursuing medicine today?
•

Becoming a physician is a marathon. Don’t
get too high when things are going well and
don’t get too low when you have a setback.
Everyone will have highs and lows; it’s just part
of the game. I recommend pursuing interests
outside of medicine. It gives you something to
look forward to and gets your mind off of work/
studying.

23. What are the fields/aspects in medicine
you feel are on rise? What fields or aspects
are on the decline?
•

•

Rise – more research-based guidelines with
strong scientific background are on the rise.
Recommendations are now, more than ever,
founded in research. Cardiology is one of
the fields that has the most scientific studies
and clinical trials. I can point to specific trials
to inform my patient why I am recommending
certain treatments. Technology advancements
are on the rise too. We have access to new tools
that make procedures less invasive.
Decline – autonomy. Many jobs now involve
being employed by others such as a hospital
system or a university. I know of physicians who
are less aggressive with patients as they fear
bad outcomes to which they have to answer to
someone who has little health care experience
and is only looking at the bottom line.

24. How has medicine affected your home
life? Do you feel that you have missed out
on any aspect of life because of medicine?
Is it possible to have a full life in your field?
•

Medical training dominates your 20s. There
will be times where you won’t be able to do
something you want to do because of work/tests/
call/whatever. Some relationships (romantic
or non-romantic) may suffer because of your
stress/hours. There are things that you will
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miss out on. However, it is definitely possible to
have a full life and have interests and pastimes
outside of medicine. One just needs to be
prepared that priorities need to be sound and
not get completely wrapped up in medicine.
You can’t do your best job if you are miserable
because you will burn out, cut corners, and not
be as diligent as you should.

Like what you see?
Apply Today!
urosmosis.com/jointeam
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